BRIEF-Lilly's Foundayo Delivers Superior A1C Control & Weight Loss In Three Type 2 Diabetes Trials

Eli Lilly

Eli Lilly

LLY

0.00

June 9 (Reuters) - Eli Lilly and Co LLY.N:

  • LILLY'S ORAL GLP-1 FOUNDAYO (ORFORGLIPRON) DELIVERED SUPERIOR A1C CONTROL AND WEIGHT LOSS IN THREE PIVOTAL TYPE 2 DIABETES TRIALS

  • ELI LILLY - TO SUBMIT FOUNDAYO FOR TYPE 2 DIABETES TO U.S. FDA BY END OF Q2

  • ELI LILLY - FOUNDAYO 17.2 MG LOWERS A1C BY 2.2% AT 52 WEEKS VERSUS 1.4% WITH ORAL SEMAGLUTIDE 14 MG

  • ELI LILLY - FOUNDAYO 17.2 MG ACHIEVES 57.1% GREATER A1C REDUCTION AND 73.6% GREATER WEIGHT LOSS VERSUS ORAL SEMAGLUTIDE 14 MG

  • ELI LILLY - FOUNDAYO MET PRIMARY ENDPOINT AND KEY SECONDARY ENDPOINTS

  • ELI LILLY - IN ACHIEVE-3 TRIAL, FOUNDAYO OUTPERFORMED ORAL SEMAGLUTIDE ACROSS PRIMARY AND ALL KEY SECONDARY ENDPOINTS

  • ELI LILLY: OVERALL SAFETY AND TOLERABILITY PROFILE OF FOUNDAYO, INCLUDING TREATMENT DISCONTINUATION RATES, WAS CONSISTENT WITH PREVIOUS STUDIES

Source text: ID:nPn3vCKya

Further company coverage: LLY.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.